EХPERIENCE IN INTERFERON β-1A USE FOR TREATMENT OF MULTIPLE SCLEROSIS IN CHILDREN
https://doi.org/10.15690/vsp.v12i5.794
Abstract
Aim: to evaluate the impact of subcutaneous interferon β-1a on matrix metalloproteinases 3, 8, 9 (MMP), cytokines (tumor necrosis factor α — TNF α, and transforming growth factor β1 — TGF β1) levels in serum of children with relapsing-remitting multiple sclerosis. Patients and methods: the results of treatment of 32 patients with relapsing-remitting multiple sclerosis aged 12–18 years (22 girls and 10 boys) were analyzed. Treatment efficacy was assessed by the number of relapsing-remitting multiple sclerosis exacerbations during 12 months, MRI data, MMP and cytokines dynamics in serum. Results: statistical evidence acquired for MMPs, their tissue inhibitor and cytokines levels decrease (p < 0,005) in patients receiving therapy with subcutaneous INF β-1a. Conclusions: subcutaneous interferon β-1а is highly efficient in treatment of relapsing-remitting multiple sclerosis in children and adolescents.
About the Authors
L. M. Kuzenkova
Scientific Centre of Children Health of RAMS, Moscow;
I.M. Sechenov First Moscow Medical State University
Russian Federation
Kuzenkova Lyudmila Mikhaylovna, Doctor of Medical Sciences, Professor, Head of the Department of Psychoneurology and Psychosomatic Pathology SCCH RAMS, Associate Professor of the Pediatrics Department with Pediatric Rheumatology Course at the Faculty of Pediatrics at I.M. Sechenov First Moscow State Medical University
Russian Federation
Kuzenkova Lyudmila Mikhaylovna, Doctor of Medical Sciences, Professor, Head of the Department of Psychoneurology and Psychosomatic Pathology SCCH RAMS, Associate Professor of the Pediatrics Department with Pediatric Rheumatology Course at the Faculty of Pediatrics at I.M. Sechenov First Moscow State Medical University
L. A. Pak
Scientific Centre of Children Health of RAMS, Moscow
Russian Federation
Russian Federation
V.M. Studenikin
Scientific Centre of Children Health of RAMS, Moscow;
N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
N. N. Shatilova
Scientific Centre of Children Health of RAMS, Moscow
Russian Federation
Russian Federation
B. I. Bursagova
Scientific Centre of Children Health of RAMS, Moscow
Russian Federation
Russian Federation
I. E. Smirnova
Scientific Centre of Children Health of RAMS, Moscow
Russian Federation
Russian Federation
References
1. Boyko A. N., Stolyarov I. D., Sidorenko T. V., Kulakova O. V., Kolyak E. V., Petrov A. M., Ilves A. G., Nikiforova I. G., Favorova O. O., Gusev E. I. Patogeneticheskoe Lechenie Rasseyannogo Skleroza: Nastoyashchee i Budushchee [Pathogenetic Treatment of Multiple Sclerosis: Present and Future]. Zhurnal nevrologii i psikhiatrii [Journal of Neurology and Psychiatry]. 2009; 109 (7, Issue 2): 90–99.
2. Schmidt T. E., Yakhno N. N. Rasseyannyy Skleroz [Multiple Sclerosis]. Moscow, Meditsina Publ., 2003. 160 p.
3. Chaudhary A. K., Singh M., Bharti A. C., Asotra K., Sundaram S., Mehrotra R. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J. Biomed. Sci. 2010; 17: 10. Doi: 10.1186/1423-0127-17-10.
4. Lopatinskaya L., Zwemmer J., Uitdehaag B., Lucas K., Polman C., Nagelkerken L. Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years. Mult. Scler. 2006; 12 (6): 704–709.
5. Boz C., Ozmenoglu M., Velioglu S., Kilinc K., Orem A., Alioglu Z., Altunayoglu V. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin. Neurol. Neurosurg. 2006; 108 (2): 124–128.
6. Candelario-Jalil E., Yang Y., Rosenberg G. A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2009; 158 (3): 983–984.
7. Mazzini F., Nuti E., Petri A., Rossello A. Immobilization of matrix metalloproteinase 8 (MMP-8) for online drug screening. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2011; 879 (11–12): 756–762.
8. Shatilova N. N. Dinamika Aktivnosti Matriksnykh Metalloproteinaz i Markerov Apoptoza pri Rasseyannom Skleroze u Detey [Activity Dynamics of Matrix Metalloproteinases and Apoptosis Markers at Multiple Sclerosis in Children]. Avtoreferat-dissertatsiya kandidata meditsinskikh nauk [Autoabstract-thesis of Candidate of Medical Sciences]. М. 2013. 24 p.
9. Boyko A. N., Lashch N.Yu., Slanova A. V., Siluyanova V. A., Kulakova O. G., Favorova O. O. Monitoring Urovnya Matriksnoy Metalloproteinazy 9 (MMP-9) v Otsenke Urovnya Patologicheskogo Protsessa u Bol'nykh s Remitiruyushchim Techeniem Rasseyannogo Skleroza [Monitoring the Level of Matrix Metalloproteinase 9 (MMP-9) in the Assessment of the Pathological Process in Patients with Remitting Multiple Sclerosis]. Neyroimmunologiya [Neuroimmunology]. 2004; II (2): 94.
10. Bernal F., Elias B., Hartung H. P., Kieseier B. C. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult. Scler. 2009; 15 (6): 721–727.
11. Kanesaka T., Mori M., Hattori T., Oki T., Kuwabara S. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2006; 77 (2): 185–188.
12. Comabella M., Rio J., Espejo C., Ruiz de Villa M., Al-Zayat H., Nos C., Deisenhammer F., Baranzini S. E., Nonell L., Lopez C., Julia E., Oksenberg J. R., Montalban X. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin. Immunol. 2009; 130 (2): 145–150.
13. Javaid M. A., Abdallah M. N., Ahmed A. S., Sheikh Z. Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview. Acta Neurol. Belg. 2013; Sep. 4. [Epub ahead of print].
14. Yilmaz U., Gucuyener K., Atak A., Aral A., Gurkas E., Demir E., Serdaroglu A. Matrix metalloproteinase-7 and matrix matalloproteinases-9 in pediatric multiple sclerosis. Pediatr. Neurol. 2012; 47 (3): 171–176.
15. Ostrand-Rosenberg S., Sinha P., Chornoguz O., Ecker C. Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunol. Immunother. 2012; 61 (8): 1319–1325.
16. Raine C. S., Bonetti B., Cannella B. Multiple sclerosis: expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque. Rev. Neurol. (Paris). 1998; 154 (8–9): 577–585.
Review
For citations:
Kuzenkova L.M., Pak L.A., Studenikin V., Shatilova N.N., Bursagova B.I., Smirnova I.E. EХPERIENCE IN INTERFERON β-1A USE FOR TREATMENT OF MULTIPLE SCLEROSIS IN CHILDREN. Current Pediatrics. 2013;12(5):24-29. (In Russ.) https://doi.org/10.15690/vsp.v12i5.794
Views:
3443
Email this article 
